• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.

作者信息

Papayannidis Cristina, Sartor Chiara, Dominietto Alida, Zappone Elisabetta, Arpinati Mario, Marconi Giovanni, Cristiano Gianluca, Nanni Jacopo, Parisi Sarah, Barbato Francesco, Paolini Stefania, Soverini Simona, Terragna Carolina, Robustelli Valentina, Testoni Nicoletta, Chirumbolo Gabriella, Curti Antonio, Cavo Michele, Bonifazi Francesca

机构信息

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.

Dipartimento di Medicina Specialistica Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.

出版信息

Hematol Oncol. 2021 Oct;39(4):580-583. doi: 10.1002/hon.2886. Epub 2021 May 7.

DOI:10.1002/hon.2886
PMID:33963566
Abstract
摘要

相似文献

1
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.在异基因干细胞移植后的复发急性淋巴细胞白血病中，奥英妥珠单抗与供体淋巴细胞输注是一种安全且有前景的联合治疗方法。
Hematol Oncol. 2021 Oct;39(4):580-583. doi: 10.1002/hon.2886. Epub 2021 May 7.
2
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.在 III 期 INO-VATE 试验中，采用奥加米星治疗复发/难治性急性淋巴细胞白血病患者的微小残留病状态的影响。
Leuk Res. 2020 Jan;88:106283. doi: 10.1016/j.leukres.2019.106283. Epub 2019 Nov 25.
3
Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.Blinatumomab 或 Inotuzumab Ozogamicin 桥接异基因造血干细胞移植治疗复发/难治性 B 系急性淋巴细胞白血病：回顾性单中心分析。
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e724-e733. doi: 10.1016/j.clml.2020.05.022. Epub 2020 Jun 3.
4
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.使用奥英妥珠单抗治疗的复发或难治性急性淋巴细胞白血病患者的周期数对治疗结果的影响
Br J Haematol. 2020 Nov;191(3):e77-e81. doi: 10.1111/bjh.17029. Epub 2020 Aug 17.
5
Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19-negative acute lymphoblastic leukemia after CAR-T cell therapy.在异基因造血干细胞移植后使用奥英妥珠单抗成功挽救了CAR-T细胞治疗后复发的CD19阴性急性淋巴细胞白血病。
Pediatr Blood Cancer. 2021 May;68(5):e28980. doi: 10.1002/pbc.28980. Epub 2021 Feb 22.
6
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.依妥珠单抗奥滨尤妥珠单抗对比既往治疗复发或难治性急性淋巴细胞白血病：来自随机、3 期 INO-VATE 研究的最终报告和长期生存随访。
Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.
7
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.在首次挽救性化疗中，采用奥加米星单抗联合 mini-hyper-CVD 的化疗免疫治疗，联合或不联合blinatumomab，对费城染色体阴性急性淋巴细胞白血病患者具有高度疗效。
Cancer. 2018 Oct 15;124(20):4044-4055. doi: 10.1002/cncr.31720. Epub 2018 Oct 11.
8
Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.因诺妥珠单抗奥佐米星在法国复发或难治性CD22阳性B细胞急性淋巴细胞白血病儿科患者中的同情用药。
Br J Haematol. 2020 Jul;190(1):e53-e56. doi: 10.1111/bjh.16732. Epub 2020 May 18.
9
A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.一组接受奥英妥珠单抗治疗的急性淋巴细胞白血病患者在异基因造血细胞移植后复发的病例系列。
Int J Hematol. 2022 Jan;115(1):69-76. doi: 10.1007/s12185-021-03217-4. Epub 2021 Sep 6.
10
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.奥英妥珠单抗在复发/难治性急性淋巴细胞白血病治疗中的作用。
Immunotherapy. 2016 Feb;8(2):135-43. doi: 10.2217/imt.15.108. Epub 2016 Jan 18.

引用本文的文献

1
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.INO-CD22：一项关于奥英妥珠单抗在复发/难治性成人急性淋巴细胞白血病患者中的安全性和有效性的多中心真实世界研究。
Cancer. 2025 Apr 1;131(7):e35820. doi: 10.1002/cncr.35820.
2
Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy.抢先使用奥英妥珠单抗根除了CD19嵌合抗原受体T细胞（CART）治疗后复发的Ph阴性急性淋巴细胞白血病中的可测量残留病灶。
Clin Case Rep. 2023 Dec 9;11(12):e8289. doi: 10.1002/ccr3.8289. eCollection 2023 Dec.
3
Editorial: Novel mechanism and strategies to overcome relapse after allogeneic stem cell transplantation.
社论：克服异基因干细胞移植后复发的新机制与策略
Front Immunol. 2023 Jul 11;14:1248270. doi: 10.3389/fimmu.2023.1248270. eCollection 2023.
4
Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.分析在移植后复发的复发/难治性 B 细胞急性淋巴细胞白血病患者中，在接受 CAR-T 细胞治疗后进行第二次同种异体 HSCT 的获益。
Front Immunol. 2023 Jul 4;14:1191382. doi: 10.3389/fimmu.2023.1191382. eCollection 2023.
5
Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions.造血干细胞移植后复发的急性淋巴细胞白血病：当前挑战与未来方向
Onco Targets Ther. 2023 Jan 14;16:1-16. doi: 10.2147/OTT.S274551. eCollection 2023.
6
Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.CD19嵌合抗原受体T细胞疗法治疗异基因造血干细胞移植后复发的急性淋巴细胞白血病患者的疗效与安全性。
Int J Hematol. 2022 Sep;116(3):315-329. doi: 10.1007/s12185-022-03398-6. Epub 2022 Jun 23.
7
Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?双特异性抗体及其他非CAR靶向疗法与异基因造血干细胞移植：能否降低毒性以改善儿童急性淋巴细胞白血病的移植结局？
Front Pediatr. 2022 Feb 2;9:795833. doi: 10.3389/fped.2021.795833. eCollection 2021.